Payment overview · 2025
General Payments
$1,393.00
86 reported records · 19 companies
Healthcare provider profile · identity verified
Bradley Daniel Page, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · WAYCROSS, GA · NPI 1265490098
Verified facts
What the public records show
CMS Open Payments records show Bradley Daniel Page, PA received $1,393.00 in general payments during 2025 across 86 reported records.
ABBVIE INC. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $222.51 | 16.0% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $150.52 | 10.8% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $145.56 | 10.4% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $142.00 | 10.2% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $110.26 | 7.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.73 | 6.2% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $82.09 | 5.9% | 5 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $79.22 | 5.7% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.56 | 4.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.68 | 3.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $47.20 | 3.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.79 | 3.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.08 | 3.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.99 | 2.6% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.80 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.23 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.00 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.01 | 1.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.77 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,393.00 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $151.51 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $145.56 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $142.00 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $134.37 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $134.37 | 9 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $110.26 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $82.09 | 5 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $79.22 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.00 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.00 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $69.60 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.60 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $59.56 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $47.20 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $44.08 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $35.99 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.00 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.01 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 62 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 316 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 210 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 209 | 56 |
| Tramadol Hcl | Tramadol Hcl | 196 | 37 |
| Gabapentin | Gabapentin | 176 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 48 |
| Metformin Hcl | Metformin Hcl | 157 | 42 |
| Omeprazole | Omeprazole | 152 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 40 |
| Losartan Potassium | Losartan Potassium | 139 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 33 |
| Furosemide | Furosemide | 133 | 40 |
| Montelukast Sodium | Montelukast Sodium | 127 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 40 |
| Potassium Chloride | Potassium Chloride | 117 | 28 |
| Alprazolam | Alprazolam | 115 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 33 |
| Lisinopril | Lisinopril | 100 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 22 |
| Simvastatin | Simvastatin | 92 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 18 |
| Prednisone | Prednisone | 85 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 22 |
| Carvedilol | Carvedilol | 76 | 22 |
| Ezetimibe | Ezetimibe | 73 | 26 |
| Mounjaro | Tirzepatide | 73 | 11 |
| Glimepiride | Glimepiride | 72 | 19 |
| Meloxicam | Meloxicam | 69 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 22 |
| Ozempic | Semaglutide | 62 | 14 |
| Azithromycin | Azithromycin | 58 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 19 |
| Celecoxib | Celecoxib | 51 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Fenofibrate | Fenofibrate | 49 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 16 |
| Sertraline Hcl | Sertraline Hcl | 47 | 13 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Eliquis | Apixaban | 45 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 33 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Rybelsus | Semaglutide | 34 | 12 |
| Clonidine Hcl | Clonidine Hcl | 33 | 13 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | 14 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Famotidine | Famotidine | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Armodafinil | Armodafinil | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Horizant | Gabapentin Enacarbil | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,393.00 · 86 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FARXIGA, General - Pain Management, INSPIRE, JARDIANCE, Kerendia, LOREEV XR, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, Sunosi, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error